Neogenomics Inc (NEO) Stock Price, Quote & News

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the pr...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 239 768 0600

Fax: 239 690 4237

Website: www.neogenomics.com

Address:

9490 NeoGenomics Way, Fort Myers, United States

topstockalerts Jun. 24 at 8:44 PM

$NEO the trend has a very natural feel to it.

0 · Reply

msufans Jun. 24 at 6:39 PM

$NEO possibility of buyout?

0 · Reply

AnyMonkey Jun. 24 at 5:35 PM

$NEO wonder whats driving todays 10% gain…

1 · Reply

bmwbuzzz Jun. 24 at 3:01 PM

$NEO and so it goes!

0 · Reply

Doozio Jun. 21 at 12:10 AM

ONTO 🐒🍌🧠⏰♾️ $NEO

0 · Reply

Kat_Harington Jun. 18 at 10:33 PM

$NEO

0 · Reply

G101SPM Jun. 17 at 12:41 PM

#DILUTION Adaptive Biotechnologies ($ADPT) prices upsized offering of $300 mln of 0% convertible senior notes due 2031 (from $250 mln); Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement NeoGenomics ($NEO) prices offering of $275 mln of 0.75% convertible senior notes due 2032 Pattern Group ($PTRN) prices offering of 8.0 mln shares of common stock at $19.00 per share SOPHiA GENETICS ($SOPH) prices offering of 10,526,000 ordinary shares at $4.75 per ordinary share

0 · Reply

bmwbuzzz Jun. 16 at 2:36 PM

$NEO Re: convertible note offering. Yes, a convertible note offering is inherently dilutive. While it delays dilution today by acting as debt, it creates a "deferred equity dilution". When the note later converts into shares, it increases the total outstanding share count, thereby reducing the proportional ownership of existing shareholders. HOWEVER - as a "loan", it can also be closed using cash. If NEO uses the $$$ to further grow revenue/profits, this can result in a non-dilutive event. Market is reacting negatively, but correcting back up appropriately.

0 · Reply

Kat_Harington Jun. 16 at 1:40 PM

$NEO someone correct me if I’m wrong here, but this is down because of the 275 million dollar convertible note offering? Effectively diluting our shares?

1 · Reply

GordoHLYK13 Jun. 13 at 2:18 PM

$HLYK $NEO $AMZN Been holding $HLYK since 2019. Started with over 800k shares pre-split under $.05 — now sitting around 8k shares with a much higher average near $5.50 after the reverse split. Yeah, the dilution and cash concerns are real, but I’m still holding because this isn’t just a tiny clinic company anymore. HLYK is building a healthcare AI/data ecosystem with telemedicine, patient integration, ARi AI, and expanding partnerships. The market only sees the struggles. I see a micro-cap trying to evolve into a scalable digital healthcare platform. If management secures funding and finally monetizes the tech, the upside from these levels could be enormous due to the tiny market cap. High risk, yes — that’s why I’m here Despite the dilution, reverse split, and survival concerns, the article confirms $HLYK is still fighting to transform itself into an AI-driven digital healthcare platform — and if they execute, the upside from these beaten-down levels could be enormous.

1 · Reply

NeoGenomics announces pricing of $275M convertible senior notes offering

Jun 17, 2026, 6:00 AM EDT - 7 days ago

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

2026-06-15T21:31:22.000Z - 9 days ago

NeoGenomics files to sell $275M of convertible senior notes due 2032

Jun 15, 2026, 5:24 PM EDT - 9 days ago

NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

Jun 4, 2026, 10:30 AM EDT - 20 days ago

NeoGenomics Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 7:05 AM EDT - 4 weeks ago

NeoGenomics to Present New Research at ASCO Annual Meeting 2026

May 21, 2026, 10:00 AM EDT - 4 weeks ago

NeoGenomics Transcript: AGM 2026

May 20, 2026, 4:20 PM EDT - 5 weeks ago

Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares

May 20, 2026, 4:15 PM EDT - 5 weeks ago

Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project

May 15, 2026, 9:05 AM EDT - 5 weeks ago

NeoGenomics to Participate in Upcoming Investor Conferences

2026-04-29T16:45:29.000Z - 2 months ago

NeoGenomics price target lowered to $11 from $13 at BofA

2026-04-29T13:42:05.000Z - 2 months ago

NeoGenomics price target raised to $14 from $13 at TD Cowen

2026-04-29T10:41:39.000Z - 2 months ago

Leerink upgrades NeoGenomics to Outperform, raises target to $25

2026-04-29T10:26:48.000Z - 2 months ago

NeoGenomics upgraded to Buy from Hold at Benchmark

2026-04-29T10:19:13.000Z - 2 months ago

NeoGenomics upgraded to Outperform from Market Perform at Leerink

2026-04-28T21:39:08.000Z - 2 months ago

NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c

2026-04-28T21:36:36.000Z - 2 months ago

NeoGenomics raises FY26 revenue view to $797M-$803M from $793M-$801M

Apr 28, 2026, 4:30 PM EDT - 2 months ago

NeoGenomics Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

NeoGenomics Earnings release: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

NeoGenomics Slides: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

NeoGenomics Quarterly report: Q1 2026

Apr 28, 2026, 4:05 PM EDT - 2 months ago

NeoGenomics Reports First Quarter 2026 Results

2026-04-23T11:26:56.000Z - 2 months ago

NeoGenomics expands access to full oncology testing portfolio

Apr 23, 2026, 7:05 AM EDT - 2 months ago

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

Apr 13, 2026, 7:05 AM EDT - 2 months ago

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

Apr 7, 2026, 7:05 AM EDT - 2 months ago

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

Apr 6, 2026, 8:00 AM EDT - 2 months ago

NeoGenomics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

NeoGenomics Proxy statement: Proxy filing

2026-03-16T11:28:54.000Z - 3 months ago

NeoGenomics PanTracer LBx test receives Medicare coverage

Mar 16, 2026, 7:05 AM EDT - 3 months ago

NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

Mar 10, 2026, 4:20 PM EDT - 3 months ago

NeoGenomics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 3:00 PM EDT - 3 months ago

NeoGenomics Slides: Investor presentation

Mar 3, 2026, 1:10 PM EST - 4 months ago

NeoGenomics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 7:05 AM EST - 4 months ago

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

2026-02-24T11:47:07.000Z - 4 months ago

NeoGenomics price target raised to $13 from $12 at Piper Sandler

Feb 17, 2026, 8:30 AM EST - 4 months ago

NeoGenomics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

NeoGenomics Annual report: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

NeoGenomics Earnings release: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

NeoGenomics Slides: Q4 2025

2026-02-17T12:45:49.000Z - 4 months ago

NeoGenomics sees FY26 adjusted EPS 16c-21c, consensus 19c

2026-02-17T12:40:53.000Z - 4 months ago

NeoGenomics reports Q4 adjusted EPS 6c, consensus 4c

Feb 17, 2026, 7:05 AM EST - 4 months ago

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 7:05 AM EST - 4 months ago

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

Jan 27, 2026, 7:05 AM EST - 5 months ago

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Jan 13, 2026, 8:15 PM EST - 5 months ago

NeoGenomics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:15 PM EST - 5 months ago

NeoGenomics Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T12:38:01.000Z - 5 months ago

NeoGenomics reports preliminary Q4 revenue $190M, consensus $188.07M

2026-01-12T12:36:33.000Z - 5 months ago

NeoGenomics CFO Jeff Sherman to retire, Abhishek Jain to succeed

CDNA

Jan 12, 2026, 7:05 AM EST - 5 months ago

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

2026-01-07T14:15:51.000Z - 6 months ago

NeoGenomics price target raised to $16 from $14 at TD Cowen

Jan 5, 2026, 7:05 AM EST - 6 months ago

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 7:05 AM EST - 6 months ago

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

Dec 15, 2025, 7:05 AM EST - 6 months ago

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

Dec 10, 2025, 7:05 AM EST - 7 months ago

NeoGenomics to Present New ctDNA Research at SABCS 2025

Dec 8, 2025, 8:05 AM EST - 7 months ago

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

Dec 2, 2025, 2:30 PM EST - 7 months ago

NeoGenomics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 2:00 PM EST - 7 months ago

NeoGenomics Transcript: Stephens Annual Investment Conference

Oct 30, 2025, 12:51 PM EDT - 8 months ago

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

Oct 28, 2025, 8:30 AM EDT - 8 months ago

NeoGenomics Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

NeoGenomics Quarterly report: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

NeoGenomics Earnings release: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

NeoGenomics Slides: Q3 2025

Oct 28, 2025, 7:05 AM EDT - 8 months ago

NeoGenomics Reports Third Quarter 2025 Results

Oct 14, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

Oct 7, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

Aug 29, 2025, 7:05 AM EDT - 10 months ago

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

Jul 30, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

Jul 29, 2025, 8:30 AM EDT - 11 months ago

NeoGenomics Earnings Call Transcript: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 11 months ago

NeoGenomics Quarterly report: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 11 months ago

NeoGenomics Earnings release: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 11 months ago

NeoGenomics Slides: Q2 2025

Jul 29, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics Reports Second Quarter 2025 Results

Jul 1, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

Jun 30, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Jun 24, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

Jun 4, 2025, 2:00 PM EDT - 1 year ago

NeoGenomics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 1:00 PM EDT - 1 year ago

NeoGenomics Transcript: 45th Annual William Blair Growth Stock Conference

May 28, 2025, 7:10 AM EDT - 1 year ago

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

May 22, 2025, 7:10 AM EDT - 1 year ago

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

May 20, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Participate in Upcoming June Investor Conferences

May 1, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings Call Transcript: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Quarterly report: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings release: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Slides: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

Apr 29, 2025, 7:30 AM EDT - 1 year ago

NeoGenomics Reports First Quarter 2025 Results

Apr 23, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics Proxy statement: Proxy Filing

Apr 22, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics Proxy statement: Proxy Filing

Apr 8, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

Apr 7, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Completes Acquisition of Pathline

Apr 1, 2025, 7:05 AM EDT - 1 year ago

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

Mar 13, 2025, 9:00 AM EDT - 1 year ago

NeoGenomics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 3:30 PM EDT - 1 year ago

NeoGenomics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 7:00 AM EDT - 1 year ago

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

Mar 4, 2025, 1:50 PM EST - 1 year ago

NeoGenomics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Earnings Call Transcript: Q4 2024

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Annual report: Q4 2024

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Earnings release: Q4 2024

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Slides: Q4 2024

Feb 18, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

Jan 29, 2025, 8:05 AM EST - 1 year ago

NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

topstockalerts Jun. 24 at 8:44 PM

$NEO the trend has a very natural feel to it.

0 · Reply

msufans Jun. 24 at 6:39 PM

$NEO possibility of buyout?

0 · Reply

AnyMonkey Jun. 24 at 5:35 PM

$NEO wonder whats driving todays 10% gain…

1 · Reply

bmwbuzzz Jun. 24 at 3:01 PM

$NEO and so it goes!

0 · Reply

Doozio Jun. 21 at 12:10 AM

ONTO 🐒🍌🧠⏰♾️ $NEO

0 · Reply

Kat_Harington Jun. 18 at 10:33 PM

$NEO

0 · Reply

G101SPM Jun. 17 at 12:41 PM

0 · Reply

bmwbuzzz Jun. 16 at 2:36 PM

0 · Reply

Kat_Harington Jun. 16 at 1:40 PM

$NEO someone correct me if I’m wrong here, but this is down because of the 275 million dollar convertible note offering? Effectively diluting our shares?

1 · Reply

GordoHLYK13 Jun. 13 at 2:18 PM

1 · Reply

bmwbuzzz Jun. 4 at 2:09 PM

$NEO Make up your mind, NEO! Appreciate the bounce back...but what is driving the 5%+ swings?!?

1 · Reply

bmwbuzzz Jun. 1 at 4:26 AM

$NEO odd that the sentiment is bearish. Guessing its from the low volume of posts.

0 · Reply

DriveForShow May. 28 at 8:06 PM

$NEO $10 was not on my bingo card this week. See if this holds. Not holding breath

0 · Reply

GordoHLYK13 May. 27 at 3:05 PM

$NEO @GambleLifeAway

0 · Reply

GordoHLYK13 May. 27 at 3:04 PM

$NEO @GambleLifeAway Boom

0 · Reply

GordoHLYK13 May. 22 at 7:48 PM

@GambleLifeAway $NEO $9.23 more to come

0 · Reply

greenlandminesltd May. 22 at 3:06 PM

$GRML has entered into an Agreement to acquire Neo North Star Resources, Inc., owner of the Sarfartoq Rare Earths Project in southwest Greenland, from its stockholders including $NEO. The transaction will add an advanced magnet rare earths asset in Greenland to complement Skaergaard and solidifies Greenland Mines’ position in the global critical minerals race. Neo Performance Materials will become a strategic shareholder and secures offtake rights for up to 60% of future Sarfartoq production. Full press release here: bit.ly/3PB8dNR

0 · Reply

GordoHLYK13 May. 20 at 6:49 PM

$NEO Trash” doesn’t pull in $600M+ in annual revenue while expanding margins and staying deeply embedded in oncology workflows. If anything, these compressed levels make NEO more attractive for a takeover. Any acquisition premium on a company with real revenue, sticky hospital relationships, and nationwide infrastructure isn’t landing at $8. The “big dogs” are burning cash trying to build what NeoGenomics already has. I’ll take proven execution over pre-revenue hype every time. 🚀 @GambleLifeAway

0 · Reply

GordoHLYK13 May. 20 at 12:13 PM

$NEO Back in 2018 I held 1k shares of NeoGenomics at a $13 average and watched it run to $60. Fast forward to 2026… now I’m holding 4k shares at $8.56 and the setup honestly looks even stronger. NEO today isn’t the same company from 2018 — bigger revenue, deeper oncology relationships, more advanced molecular testing, AI-driven diagnostics, and expanding precision medicine exposure. While everyone chases hype, NEO is quietly building a real cancer diagnostics powerhouse. The business is making substantially more money than it was during the last major run, yet the stock trades at a fraction of those levels. If execution keeps improving and margins expand, this could easily feel like NeoGenomics 4.0. 🚀 $NEO making way more money than the 2018 run to $60… yet trading near $8. Different beast now — stronger tech, bigger oncology footprint, AI diagnostics growth, and huge upside if sentiment flips. NeoGenomics 4.0 loading. 🔥 $TEM $NTRA $GH $EXAS

1 · Reply

GordoHLYK13 May. 19 at 1:35 PM

$NEO Vague insults aren't an argument. If you actually have a point to make about $NEO's clinical footprint or genomics landscape, make it. If not, hit the unfollow button. $NEO quietly became the backbone of oncology testing. Deeply integrated with major hospital systems, growing NGS revenue +26%, and locking in clients through Epic Aura integration. Revenue keeps climbing while Wall Street still sees major upside if margins improve. At $8S, bulls see a turnaround story before profitability catches up. $PFIZER.NSE

1 · Reply

GordoHLYK13 May. 17 at 4:50 PM

$HYLN I got my gains, but those holding or buying at these levels should stay aware. $HYLN still has a long road between hype and real commercial revenue. The shelf registration is sitting there ready, and historically companies use big rallies to raise cash with less dilution pain. Yes, they still have cash, but scaling manufacturing, hiring talent, and building out KARNO production burns money fast. LOIs are not guaranteed revenue, and major validation timelines stretching into 2028/2029 means meaningful cash flow could still be years away. The tech story is interesting, but investors chasing momentum here should understand the balance sheet risk, dilution possibility, and long execution timeline before getting overly bullish. Congratulations for those who held. I sold too soon. Congrats to everyone who held through the volatility and locked in gains on $HYLN. The move was solid. As for me, I’ve shifted gears and I’m now fully invested in $NEO

1 · Reply

GordoHLYK13 May. 17 at 4:24 PM

$NEO $NEO isn’t growing from basic lab tests anymore… they’re transforming into a high-margin precision oncology machine. • NGS revenue exploded +26% YoY — that’s the real money-maker with premium pricing and higher margins. • Revenue hit $187M while average revenue per test climbed to $495, showing strong demand for advanced cancer sequencing. • The new Epic Aura integration is a sleeper mega catalyst — thousands of hospitals can now order NeoGenomics cancer testing directly inside Epic with one click. Massive pipeline expansion. • Operating expenses dropped while EBITDA jumped +27%, proving scale and efficiency are finally kicking in. • Wall Street still sees upside with $13–$15 PTs while the stock sits near $8 range after the pullback. NeoGenomics is evolving from a traditional lab company into a precision oncology data powerhouse with accelerating NGS growth, expanding hospital access, and improving margins. Bulls are betting this is the phase before profitability and re-rating

0 · Reply

Market Cap	1.46B
Revenue (ttm)	727.33M
Net Income (ttm)	-108.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-14.85%
Debt to Equity Ratio	0.00

Volume	6,050,200
Avg Vol	2,458,860
Day's Range	N/A - N/A
Shares Out	130.21M
Stochastic %K	80%
Beta	1.82
Analysts	Strong Sell
Price Target	$15.05